Get started

PHARMA

Novo Nordisk (NVO) 1WI’m looking at the weekly NVO chart as of late December 2025, and this is no longer about fear or headlines. It’s about structure and valuation. After a powerful multi year rally from 2022 to 2024, the stock went through a deep and healthy correction. In 2025, price built a strong weekly demand base around the 50–55 USD area, where volume profile, historical support and long term buyers align. Selling pressure is fading, volatility is compressing, and price action is stabilizing. Technically, NVO is transitioning into a post correction accumulation phase. On the weekly timeframe, RSI has recovered from oversold territory and is holding a neutral bullish range. MACD is forming a constructive reversal structure, while declining volume on down moves suggests exhaustion rather than distribution. As long as price holds the weekly base and does not break lower, the recovery scenario remains valid, with upside reference zones near 72–75 USD and later 90–92 USD if momentum confirms. From a fundamental perspective, as of the end of 2025, Novo Nordisk remains one of the highest quality businesses in global healthcare. Revenue exceeds 39 billion USD, with the Diabetes and Obesity Care segment generating more than 85% of total sales, continuing to show resilient growth. The United States and Europe remain the core revenue drivers, while international markets continue to expand steadily. Cash flow quality remains strong. Operating cash flow is above 18 billion USD on a TTM basis, free cash flow stays positive despite heavy investments into capacity expansion and R&D. Dividend policy remains disciplined and shareholder friendly, with TTM dividend yield around 2.3% and a payout ratio near 35–36%, leaving room for both reinvestment and future dividend growth. What matters is that the 2025 correction did not come with any structural deterioration of the business. This was not a business breakdown, but a valuation reset after an extreme growth phase. Expectations have been normalized, multiples compressed, while fundamentals stayed intact. That’s where asymmetry begins to emerge. Tactically, I see NVO as a long term quality compounder, where 2025 served as a reset year. As long as the weekly structure holds, the path for gradual upside remains open. This is not a short term trade, but a trend rebuilding phase driven by cash flow, market leadership and scale. Sometimes the best opportunities appear not at peak optimism, but when the market has already done its emotional damage and the numbers are still standing.
NYSE:NVOLong
by TotoshkaTrades
7
HINOON📊 HINOON (PSX) – Daily & Weekly Technical Setup HINOON has made a fresh all-time high and is now retracing to the 0.5 Fibonacci level, forming a textbook continuation setup for HHHL (Higher High, Higher Low) structure 📈 🔹 Daily & Weekly trend: Bullish 🔹 Retracement: 0.5 Fib – healthy pullback 🔹 Structure: Trend intact, continuation likely 🎯 Targets: TP1 – as marked on the chart TP2 – as marked on the chart 🛡️ Risk Management: Strict stop-loss below invalidation Maintain favorable risk-to-reward 🧩 Fundamental Verdict (Strong Support) 💊 HINOON is fundamentally a strong pharmaceutical company in Pakistan: ✅ Consistent growth in revenue & profit ✅ Attractive margins vs industry peers ✅ Solid dividend history ✅ Ongoing export expansion 📌 Conclusion: Technical continuation + strong fundamentals = high-probability setup ➡ Trade with discipline, not emotions.
PSX:HINOONLong
by SmartMoney-AR
ESPR 1W: cholesterol therapy for patients and investors alikeEsperion Therapeutics (ESPR) has broken its long descending trendline and retested the $2.4–$2.6 support area, forming a solid triple bottom with rising volume. The stock is now holding above key moving averages, signaling accumulation. While above $2.5, the technical setup points to a move toward $6.4, aligning with major resistance and the 200-week MA. Fundamentally, the company enters one of its strongest phases in years. Following earlier liquidity struggles, Esperion has stabilized its operations and regained investor confidence. The core growth driver is Nexletol (bempedoic acid), a non-statin cholesterol-lowering therapy for patients intolerant to statins. In 2025, combined Nexletol and Nexlizet sales jumped over 45% year-on-year, surpassing $170 million for the first nine months. Recent safety data were positive, leading to new approvals across Europe and Japan - expanding partnerships and licensing revenues. Cash position strengthened via milestone payments from Daiichi Sankyo and Viatris, reducing debt and supporting R&D without new dilution. Challenges remain: profitability is still out of reach, as marketing and development expenses stay high, though liquidity provides breathing room. The broader biotech sector’s rebound amid rate-cut expectations adds tailwind to revenue-backed small caps like Esperion. Tactically, holding above $2.5 keeps the bullish trajectory intact toward $6.4. A weekly close below $2.3 would negate the setup and re-test lower support, though current accumulation favors the upside. Esperion helps reduce cholesterol - ironic that its chart still raises investors’ heart rate.
NASDAQ:ESPRLong
by TotoshkaTrades
VKTX Viking Therapeutics Exploding Higher TodayVKTX surges higher today after pulling back again near 200-day EMA. Not sure what the news is that's driving the big move higher. The news I did find talks about the following: 1) Viking Therapeutics completed a drug clinical trial stage earlier than expected last week 2) VKTX is on lists of hot stocks to buy for 2026 and could be a takeover, acquisition target 3) VKTX is recommended by 15 Wall Street Ranked analysis who give stock 12-month consensus average price target of $92 4) VKTX is on lists of stocks with high short interest (over 20% short interest) TO BUY because they are vulnerable to getting short-squeezed Let's talk about the 4th item above. Just imagine VKTX continues to move higher on good news about clinical trials or possibly getting acquired by a larger company. This would push the stock even higher and will force traders who have big short positions on the stock to quickly cover, creating a snowball effect that frantically drives VKTX even higher and completely surges! This is reminiscent of what happened to Game Stop (GME) a few years back. I hope that this happens because I am long on several rather large call option positions on VKTX! Whatever you all decide to do..... Good Luck!
NASDAQ:VKTXLong
by VTrade52
Eli Lilly: The Trillion-Dollar Cure for Market Volatility?Eli Lilly has officially shattered the Silicon Valley ceiling, becoming the first healthcare company to achieve a $1 trillion market capitalization. While tech giants like Nvidia grapple with bubble concerns and doubts about AI monetization, Lilly has delivered tangible, recurring revenue through its dominance of GLP-1. This milestone is not merely a pharmaceutical victory; it represents a fundamental shift in market leadership from speculative tech to essential biopharma. Macroeconomics: The Flight to Quality The Federal Reserve’s pivot is fueling this ascent. New York Fed President John Williams signaled imminent rate cuts, raising December cut expectations to 70%. Lower rates disproportionately benefit capital-intensive sectors like pharma, which require massive upfront R&D and manufacturing spend. Investors, wary of tech volatility, are treating Lilly as a "defensive growth" asset—a rare hybrid offering the stability of healthcare with the explosive growth of software. Science & Innovation: The Dual-Agonist Revolution Lilly’s valuation rests on **tirzepatide** (branded as Mounjaro and Zepbound). Unlike previous drugs that target a single hormone, tirzepatide mimics both GIP and GLP-1, delivering superior efficacy in weight loss and blood sugar control. This scientific leap has rendered competitors’ single-agonist drugs vulnerable. Furthermore, Lilly is already stress-testing its own dominance with **retatrutide**, a triple-agonist candidate showing even higher potency, effectively cannibalizing its own portfolio before rivals can catch up. Business Models: Disrupting the Middlemen Lilly is aggressively rewriting the pharmaceutical distribution playbook. The launch of **LillyDirect** bypasses traditional Pharmacy Benefit Managers (PBMs). By partnering directly with Walmart to offer cash-pay options for Zepbound vials, Lilly captures margin previously lost to intermediaries. This Direct-to-Consumer (DTC) model exerts immense pressure on insurers to cover these drugs, leveraging patient demand as a battering ram against restrictive formularies. Geostrategy: Manufacturing Sovereignty Management recognizes that demand is useless without supply. Lilly has committed over $27 billion to manufacturing expansion, predominantly in the US and Europe (Ireland and Germany). This strategy reduces reliance on fragile Asian supply chains, insulating the company from US-China geopolitical friction. By onshoring active pharmaceutical ingredient (API) production, Lilly positions itself as a national security asset, aligning corporate growth with Western industrial policy. Technology & Cyber: AI-Driven Discovery Lilly is moving beyond traditional wet labs. The company’s **TuneLab initiative** utilizes federated AI learning. This allows biotech partners to train models on Lilly’s proprietary data without exposing the underlying IP. Additionally, partnerships with Isomorphic Labs aim to accelerate small molecule discovery. This "tech-forward" approach reduces the years-long timeline of drug discovery, turning R&D into a computational problem rather than a biological guessing game. Management & Leadership: The Ricks Doctrine CEO David Ricks has executed a masterclass in capital allocation. While peers engaged in share buybacks, Ricks poured capital into manufacturing capacity ahead of approval. His leadership style is characterized by "preemptive scale"—building the factory before the drug is approved. This risk appetite allowed Lilly to meet the explosive demand for Zepbound faster than competitors, securing market share through sheer logistical brute force. Patent Analysis: Building the Moat Lilly is fiercely defending its IP territory. The company has launched legal offensives against compounding pharmacies attempting to sell unauthorized versions of tirzepatide. Simultaneously, they are layering patents on delivery mechanisms and combination therapies. The transition from auto-injectors to vials also serves a strategic patent function, complicating the regulatory pathway for future biosimilars. Conclusion Eli Lilly has successfully decoupled itself from the broader healthcare index. By combining Silicon Valley-style innovation with industrial-scale manufacturing, it has created a $1 trillion moat. As the Fed eases policy, Lilly stands ready to deploy cheap capital to further widen the gap against its rivals.
NYSE:LLYLong
by TradeThePool
Can Integration Save CVS or Sink It?CVS Health confronts a dangerous convergence of risks that threatens its vertically integrated business model. The company's Pharmacy Benefit Manager (PBM) subsidiary, Caremark, faces intensifying regulatory scrutiny as lawmakers target the opaque rebate structures and spread pricing mechanisms that underpin PBM profitability. Simultaneously, the explosive growth of high-cost GLP-1 weight-loss drugs has created unprecedented formulary pressure. CVS's decision to exclude Eli Lilly's Zepbound in favor of Novo Nordisk's Wegovy, based purely on price, backfired spectacularly. Lilly publicly pulled its employees from CVS's PBM plan and shifted to competitor Rightway Healthcare, signaling deep market skepticism about CVS's ability to balance cost control with clinical outcomes. This defection validates concerns that major employers are increasingly willing to abandon the "Big Three" PBMs for transparent alternatives.   The company's acquisition strategy has proven economically disastrous, with CVS recording a staggering $5.7 billion goodwill impairment charge on Oak Street Health in Q3 2025, effectively admitting the primary care assets were dramatically overvalued. This massive write-down undermines the core thesis that vertical integration of insurance (Aetna), PBM (Caremark), and care delivery creates synergistic value. Meanwhile, operational margins erode from multiple directions: $833 million in litigation charges from past business practices, declining generic dispensing rates as expensive branded GLP-1 drugs displace generics, and the structural reality that robust patent protection on GLP-1 drugs extending into the 2040s eliminates the PBM's traditional leverage of threatening generic competition.   CVS faces additional systemic vulnerabilities across geopolitical, technological, and scientific domains. The company's reliance on Active Pharmaceutical Ingredients sourced from China and India exposes it to supply chain disruptions, tariffs, and mandatory but expensive domestic manufacturing mandates. Its vast integrated infrastructure creates an attractive single point of failure for cyberattacks, heightened by the $20 billion technology investment to further interconnect all segments. Most critically, pharmaceutical manufacturers hold unprecedented leverage due to the extended patent exclusivity of breakthrough GLP-1 therapies, with no meaningful generic relief for 15-20 years, forcing CVS into a perpetual choice between excluding superior drugs and losing clients, or accepting coverage that severely erodes margins.   Until CVS demonstrates sustainable PBM client retention among major employers, successful integration of its healthcare delivery assets without further impairments, and a viable strategy to navigate the regulatory assault on traditional PBM economics, the investment profile remains fundamentally challenged. The Lilly defection represents more than a single client loss; it exposes structural fragility in a business model increasingly misaligned with market demands for transparency, clinical appropriateness, and technological innovation.
NYSE:CVSShort
by UDIS_View
SWING IDEA - NEULAND LABNeuland Lab , a niche API manufacturer with strong export presence and leadership in complex molecules, is offering a technically strong swing trade opportunity from key support levels. Reasons are listed below : 11,500 zone acting as a crucial support area Formation of a hammer candle on the weekly timeframe, signaling potential reversal Reversing from the 0.618 Fibonacci retracement zone – the golden pocket Taking support at the 50-week EMA , holding long-term trend structure Target - 14900 // 17600 Stoploss - weekly close below 10215 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:NEULANDLABLong
by Visionary_Growth_Insights
Teva: The flag’s ready — someone just needs to hit “launch”Teva Pharmaceutical (TEVA) is setting up for a potential continuation move after a clean impulse. On the daily chart, we have a textbook bull pennant — and not just any sloppy one. Price has broken above the 200-day moving average, and all key EMAs (50/100/200) now sit below price, confirming a solid bullish structure. Volume behavior fits the script: declining inside the pennant, signaling pressure is building. More importantly, the Volume Profile reveals a low-volume void above current levels — meaning there’s little resistance until we hit the $22+ zone. In other words, once this breaks, it could run fast. RSI is comfortably in bullish territory without being overheated, and the flagpole projection gives us clean upside targets: – Entry: breakout above pennant resistance – Target: $22.80 — full flagpole height – Support: $17.60 — confluence of 0.5 Fib + volume base TEVA isn’t asking for confirmation anymore — it’s showing it. All systems are technically armed. Now we just wait for the market to press the button.
NYSE:TEVALong
by TotoshkaTrades
3
AVDL on the way to macro resistance Price continues to follow the trend structure outlined since August and is showing strong follow-through from the mid-term support mentioned last week. As long as price is holding above the 21 EMA, I’m watching for upside momentum to extend toward the 19–21 macro resistance zone. Chart: Previously: • On upside potential (Oct 14): Chart: www.tradingview.com • On mid-term support (Oct 3): Chart: www.tradingview.com • On resistance and support (Aug 27): Chart: www.tradingview.com
NASDAQ:AVDL
by artemfedorov
ELI LILLY COMPANY - STOCK REPORTExecutive Summary Eli Lilly and Company (LLY) has delivered strong revenue and profit growth driven by blockbuster GLP‑1 therapies (Mounjaro, Zepbound) and continued pipeline progress in oncology and cardiometabolic indications. As of 26 Sep 2025 the company shows robust margins, strong free cash flow and a leading competitive position in obesity/diabetes. Key risks include increased competition (notably Novo Nordisk), formulary decisions (payer mix), pricing/regulatory pressure and execution risk in manufacturing scale‑up. Valuation is elevated versus the broader healthcare sector but appears reasonable relative to growth; a simplified DCF (base case) and comparable‑multiples view imply a fair value near mid‑single‑digit percentage above recent prices. Recommendation: Hold — favourable fundamentals but limited near‑term upside versus valuation and meaningful execution/competitive risks. 1) Key data & company overview Name: Eli Lilly and Company Sector: Pharmaceuticals / Biotechnology Primary market: NYSE (US) Ticker: LLY Brief business description Revenue model: Prescription drug sales (product sales), services (partnered R&D/licensing), royalties. Principal products: Mounjaro (tirzepatide) — T2D/weight management; Zepbound (semaglutide for weight loss comp’d), Trulicity, Humalog (insulin legacy portfolio), oncology candidates (investigational/approved). Geographic exposure: Global — largest sales in U.S., substantial Europe and row markets. Market & share metrics (most recent available — see sources) Market capitalization: ~USD 642–702 billion (source dispersion; SEC shares outstanding 946.46M as of 4 Aug 2025) Shares outstanding: 946,456,759 (per 10‑Q, Aug 4, 2025) Float: ~946M (per public filings) Last close (around 26 Sep 2025): ~USD 714–742 (sources vary intraday); use USD 714.59 (MLQ / market snapshots) as reference. P/E (trailing / consensus forward): TTM P/E ~49; next‑FY consensus ~30 (see market data). EV/EBITDA (market snapshots): ~38x (site snapshots). Price performance (approx., source snapshots to 25–26 Sep 2025): 1D: -3.7%; 1M: -4% to -8% range; 3M: -10% to -15%; 1Y: down ~20% from 52‑week high (use precise values in sources below). (Notes: market figures vary by data vendor; SEC 10‑Q provides authoritative share count. All market prices quoted are approximations from public market data as of 26 Sep 2025 — see Sources.) 2) Financial results — consolidated summary (historical 3 years + last 4 quarters) Sources: Eli Lilly SEC filings (10‑K 2024, 10‑Q Jun 30 2025), company press releases, market data sites (Yahoo/MLQ/FactSet snapshots). All amounts USD. Annuals (selected items; amounts in billions except EPS in USD) 2022 (FY): Revenue ≈ 28.3; Net income ≈ 5.16; Diluted EPS ≈ 5.41; FCF ≈ 8.0 (approx). 2023 (FY): Revenue ≈ 40.5; Net income ≈ 11.0; Diluted EPS ≈ 12.99; FCF ≈ 11.5. 2024 (FY): Revenue ≈ 45.0; Net income ≈ 10.6; Diluted EPS ≈ ~12.00; FCF ≈ ~12.0. (Notes: 2023–2024 saw large revenue step from GLP‑1 products; numbers approximated from company reports and market summaries—see Sources for exact line items.) Most recent four quarters (approx, Q3 2024 – Q2 2025) Q3 2024: Revenue ≈ 9.5B; Net income ≈ 2.2B; EPS diluted ≈ 2.32 Q4 2024: Revenue ≈ 11.0B; Net income ≈ 2.6B; EPS ≈ 2.73 Q1 2025: Revenue ≈ 14.0B; Net income ≈ 3.8B; EPS ≈ 4.2 Q2 2025: Revenue = 15.56B (company release Aug 7, 2025); Net income ≈ 4.9B; EPS (reported) ≈ 6.31 (last quarter’s EPS per consensus/press) YoY growth / trends (high level) Revenue CAGR (2022–2024): ~30–35% driven by Mounjaro/Zepbound launch adoption and price/volume mix. Net income: large increase 2022→2023; 2024 flattening due to investments, higher operating costs and mix. Q1–Q2 2025 continue strong growth. Margins: Operating margin expanded materially vs pre‑GLP era; recent operating margin ~35–38% (site snapshots). Net margin ~23–25%. Tabular snapshot Table: (Year | Revenue | Net income | Diluted EPS | FCF) 2022 | 28.3B | 5.2B | 5.41 | ~8.0B 2023 | 40.5B | 11.0B | 12.99 | ~11.5B 2024 | 45.0B | 10.6B | ~12.0 | ~12.0B Last 4Q (sum) 2024Q3–2025Q2 | ~50.1B | ~14.5B | (trailing EPS approx) 3) Balance sheet & liquidity (latest quarter Jun 30, 2025 unless noted) Key items (USD, rounded) Cash & equivalents: ~3.1–3.4B (per June 30, 2025 XBRL snippet) Current assets: (per 10‑Q) — refer to consolidated balance sheet; working capital positive. Total debt: ~38–40B (notes due 2026/2030; total debt around $39.9B per market snapshot) Net debt: ~36B (total debt minus cash) Ratios (approx) Current ratio: ~1.15 Quick ratio: ~0.89 Debt/Equity: vendor snapshots differ; leverage measured as Debt/Total Capital moderate given high cash flow (Total Debt/Enterprise Value small % per some snapshots). Commentary on solvency/liquidity Strong operating cash generation and large market cap provide ample capacity to service debt and fund capex/R&D. Short‑term liquidity adequate; interest coverage is strong given high EBITDA and cash flow. Material execution risk arises if GLP‑1 pricing or demand deteriorates sharply—could stress near‑term growth assumptions but balance sheet remains investment grade in profile. 4) Cash flow (latest 4 quarters, approximate) Operating cash flow (TTM): ~17–18B Capital expenditures (TTM): ~1.5–2.0B (increased manufacturing capex in 2024–2025) Free cash flow (TTM): ~15–16B Commentary Cash generation is robust and supports capex, share repurchases and dividend; capex is elevated for capacity expansion but remains a modest share of operating cash flow. FCF margin is strong and sustainable if product demand persists. 5) Comparable valuation (peers) — snapshot multiples Peers chosen: Novo Nordisk (NVO), AstraZeneca (AZN), Amgen (AMGN), Regeneron (REGN) — peer set focused on diabetes/biotech large caps. Table (approximate multiples — market data as of 26 Sep 2025) LLY: P/E ~49 (TTM), EV/EBITDA ~38, P/S ~15 NVO: P/E ~35, EV/EBITDA ~28, P/S ~10 AMGN: P/E ~20, EV/EBITDA ~12, P/S ~4 REGN: P/E ~25, EV/EBITDA ~15, P/S ~6 Comment: LLY trades at premium to large pharm/biotech peers reflecting superior growth from GLP‑1 franchises and margin profile; premium justified only if growth and pricing hold. 6) Fair value estimate — Simplified DCF (base case) Assumptions Base year unlevered free cash flow (FCF) = USD 15.5B (TTM approximate). Explicit forecast horizon = 5 years. FCF growth: Year1–2: +10% then Year3: +8%, Year4: +6%, Year5: +4% (reflecting moderation as market saturates and competition intensifies). Terminal growth rate = 3.0% (long‑term GDP/inflation real+inflation). WACC = 8.5% (reflects large cap pharma, low beta, moderate leverage). Calculation (rounded) Projected FCFs: Year1: 17.05B; Year2: 18.76B; Year3: 20.26B; Year4: 21.48B; Year5: 22.34B Terminal value at end Year5 = Year5*(1+g)/(WACC−g) = 22.34*(1.03)/(0.085−0.03) ≈ 22.34*1.03/0.055 ≈ 418.5B Discount PV of FCFs + terminal (discounted at 8.5%) ≈ PV(FCFs) ~ (sum PV FCFs) ≈ 72–80B + PV(Terminal) ≈ 300–330B → Enterprise value ~380–410B. Net debt (~36B) → implied equity value ≈ 344–374B. Divide by shares outstanding (946.5M) → implied fair price ≈ USD 363–395 per share. Observation: The simplified DCF produces a materially lower fair value than market cap — this stems from conservative growth fade and relatively low WACC; however market prices imply much higher expectations (market cap ~650–700B). Discrepancy suggests market pricing embeds either higher sustained FCF growth, lower discount rate, or different terminal assumptions. Because LLY’s current market cap and observed multiples are much higher, applying market‑implied expectations leads to a higher implied fair value (consistent with P/E ~49). For investors, using the simplified DCF above suggests the stock may be fully valued or richly priced unless strong multi‑year growth persists. Sensitivity WACC ±1% (7.5% / 9.5%) with base growth: implied price range roughly USD 470 (WACC 7.5%) to USD 295 (WACC 9.5%). Terminal growth ±1% (2% / 4%): price moves roughly USD −60 / +90 vs base. (Notes: DCF is simplified and uses rounded FCF; full model should use operating projections by product, tax, capex schedule. If instead one applies market multiples to 2026E EBITDA, implied prices vary widely — see sources.) 7) SWOT Strengths Market leader in next‑gen GLP‑1/dual agonists (rapid adoption). Strong gross & operating margins; robust FCF generation. Diversified pipeline (oncology, CV) and global commercial footprint. Experienced management, strong manufacturing investment. Weaknesses High valuation multiples implying little margin for error. Dependence on a few high‑revenue products (Mounjaro/Zepbound). Manufacturing scale‑up challenges and supply chain concentration risks. Increasing SG&A/R&D investment could press short‑term margins. Opportunities New indications (cardio‑protective label for tirzepatide), oral incretins (orforglipron) could expand market. International expansion and formulary wins. Bolt‑on M&A to diversify revenue streams. Threats Intense competition (Novo Nordisk market share, formulary dynamics). Payer reimbursements, pricing caps, regulatory scrutiny. Potential adverse trial/regulatory outcomes for pipeline assets. Macroeconomic/tighter capital markets affecting healthcare spend. 8) Key risks, catalysts & timeline Primary risks Competitive pressure from Novo Nordisk (Wegovy/Ozempic), payer formulary preferences (e.g., CVS formulary moves). Regulatory/pricing risk (US and international). Execution: supply chain, manufacturing scale, and successful indication expansions. Concentration risk: heavy revenue share from GLP‑1 franchise. Near‑term catalysts & timeline (next 12 months approximate) Q3 2025 earnings release (expected Oct–Nov 2025; company calendar/earnings dates per IR). FDA/regulatory milestones for label expansions / approvals for oral incretins or oncology programs (dates vary; watch company pipeline calendar). Quarterly sales updates and guidance adjustments — next: Q3 2025 release. (Precise dates: refer to investor relations events page and SEC filings; earnings typically quarterly — check IR for confirmed dates.) 9) Recommendation & risk positioning Recommendation: Hold, with possible "Buy the Dip" scenario. Rationale: Strong fundamentals and cash generation support a positive long‑term outlook, but the stock trades at elevated multiples that already price in sustained high growth; meaningful execution/competitive downside could compress the valuation. Hold for investors with neutral risk appetite; consider trimming positions for valuation‑sensitive portfolios and adding on material pullbacks or clearer evidence of sustained mid‑teens revenue growth beyond 2026. Suggested horizon: Medium term (12–24 months) for monitoring catalysts; long term (3–5 years) only if comfortable with pipeline and competitive dynamics. Risk/return profile: Medium risk / moderate to high reward conditional on continued GLP‑1 dominance and successful pipeline commercialization; downside risk if market share or pricing erodes. 10) Sources & data date Primary sources used (data current through 26 Sep 2025): Eli Lilly & Company SEC filings: Form 10‑Q for quarter ended June 30, 2025 (SEC.gov). Eli Lilly Q2 2025 results press release (Aug 7, 2025) and investor presentations (company IR). Market data snapshots and summaries: MLQ.ai, Yahoo Finance, Fox Business / FactSet quotes (price, multiples, market cap, performance snapshots). News: Yahoo Finance, PR Newswire coverage of Q2 2025 results.
NYSE:LLYLong
by dPEngineering
Kenvue Tylenol Turmoil: Does the 33% Drop Scream Undervalued?While many stocks (especially tech) are near all-time highs and have high PE ratios, I'm still hunting for bargains, and Kenvue seems to be relatively cheap. More recently, it came under fire because of Trump's remarks on Tylenol, and the stock lost over 10% in a few days. Since May 2025, the stock has lost 33%, putting it, in my opinion, in an undervalued zone. Kenvue is the manufacturer of a bunch of health-related products, including Tylenol, Neutrogena, Band-Aid, Listerine, Benadryl, Zyrtec, Motrin, Aveeno, Johnson's, Rogaine, and many more. I like this kind of health-related beaten-down stocks because they exhibit good uncorrelation with the rest of the stock market, and in bear markets, they tend to hold up well because people always need to buy healthcare products. WHY BUY KENVUE STOCK? The stock has a strong moat, with excellent market penetration, top-of-mind brand recognition, and consumer loyalty, as well as economies of scale, worldwide. They have great management, with Kirk Perry and Andy Dasgupta leading the company. This guy has a great track record in the consumer product sector. Despite the decent performance, the stock price is now at an all-time low. KEY NUMBERS AND FUNDAMENTALS Where should I start... Since they spun off from Johnson & Johnson, the stock is now the cheapest when compared to their revenue, income, and other metrics. Diluted EPS is now at $0.22. The same level as in 2023, when the stock was at $24. The difference is that the stock is now at $16 (33% cheaper). The dividend ratio is now at 5%, the best level ever. The last time it was this close to the current level was in mid-2024, when the dividend yield reached 4.6%. After that, the stock rose by 38% in less than 6 months. If you like dividends, you should definitly take a look at Kenvue. The PE ratio is 22, which is low compared to the sector and the company's historical data. Similar story for the PB ratio, which is now at an all-time low. This data is telling us that the stock is comparatively cheap. Of course, one needs to ask: Is it cheap because of poor prospects for the company, or because the market is overly fearful? I'd lean for the second. It's also worth adding that their gross margin is 58%, the EBITDA margin is 24% (quite good), and the forward PE is at around 15. Finally, the analyst's price targets average $22, giving it an upside of around 34%. MY GAMEPLAN I'm going to allocate close to 1% of my net worth to this stock. In case the price drops, I will average down my purchasing price, considering that this company is likely to continue having a very strong moat for the coming years. I plan to hold it for the medium/long term, potentially selling part or the entirety of my holdings once I get over 30% return. I will re-evaluate it later this year. Quick note: I'm just sharing my journey - not financial advice! 😊
NYSE:KVUELong
by HenriqueCentieiro
2
Eli Lilly (LLY) – Pharma Giant at a Key Price LevelHi, Eli Lilly & Co. is one of the world’s largest pharmaceutical companies, founded in 1876 and headquartered in Indianapolis. It operates in over 125 countries and is best known for blockbuster treatments in diabetes, obesity, oncology, and immunology. Recent growth has been driven largely by its GLP-1 class drugs Mounjaro and Zepbound, which have quickly become industry leaders in the weight-loss and diabetes markets. Recent Fundamentals (Q2 2025) Revenue: $15.56 B (+38% YoY) - EPS: $6.31 (beat expectations) - Mounjaro sales: $5.2 B - Zepbound sales: $3.38 B - Full-year guidance: Revenue $60–62 B, EPS $21.75–$23.00 - Margins: Gross margin ~82.6%, net margin ~25.9% - Profitability: ROE ~75.5%, ROIC ~29.6% While fundamentals remain strong, the recent Phase III data for the oral weight-loss pill orforglipron came in below expectations, sparking a ~14% drop, the stock’s steepest one-day decline in decades. Analysts have since trimmed long-term sales forecasts for this product. From a valuation perspective, the stock trades at a premium (~41× P/E, ~10.7× P/S), leaving little room for major disappointments. Technicals Technically speaking, the price has arrived in the zone where I’ve been patiently waiting to share it as an idea. This is a good area from where to start building positions if you’re interested. There are quite a few technical confluence factors aligning here, but be ready to grab it also around $500 if the market offers it. Let that be your guide: - If you’re not willing to hold long-term, don’t touch it. - If you’re not willing to buy more at lower prices, don’t touch it. Good luck, Vaido
NYSE:LLYLong
by VaidoVeek
SIDO On the Crossroads?SIDO was a VERY reliable asset on my portfolio since the pandemic. It fell in the aftermath, but we can always hope for a meaningful recovery as the company is pretty much perfect on the books. But it fell so hard since mid-2024. I stopped buying SIDO since then, though I still keep it on my portfolio for the sake of dividends. Now, I am thinking of buying it again. On June, SIDO has touched multi-year lows under 500. Then it slowly woke up to just slightly above 500 now. Sufficient reasons to think it may temporarily go sideways or rise till the next stopover at 600-ish.
IDX:SIDOLong
by SINAUSAHAM
Nifty is bullish but the concern is...Total Volume and closing were strong today — that’s a good sign. But the only concern is that sellers' volume was 218 million more than buyers. That’s a big gap and something we can’t ignore. NSE:NIFTY Pivot is at 24,524, and Pivot Percentile is 0.29% — that’s slightly high, so expect volatility. If Nifty opens with a gap down and then sustains above the Pivot for 1 hour, we might see a good upside, and it would be worth chasing. A gap-up open won’t be ideal — a controlled open near the pivot is better. Apart from sellers’ volume, everything else looks bullish. Even the options data is pointing toward a move up, with a target zone near 24,800. So, my view for tomorrow is cautiously bullish. NSE:BANKNIFTY is looking much stronger than Nifty. This time, the rally might be led by NSE:CNXPSUBANK . - Support: 55,294 - Resistance: 55,650 If BankNifty moves, chances are Nifty will follow as well. Top Sectors to Watch: NSE:CNXIT NSE:CNXPHARMA If you remember, I had mentioned earlier — this time when the market starts bouncing back from the bottom, IT sector will be the first to run. That’s all for today. Plan your trade and Trade your plan. Take care. Have a profitable tomorrow.
NSE:NIFTY
by Trendxinc
BridgeBio – Blockbuster Launch Fuels Global Biotech Momentum Company Snapshot: BridgeBio Pharma NASDAQ:BBIO is transitioning into a commercial-stage growth story, anchored by its breakthrough ATTR-CM therapy Attruby (acoramidis) and a deep genetic disease & oncology pipeline. Key Catalysts: Attruby Launch Off to a Strong Start 🚀 $36.7M in first full-quarter sales from 2,072 unique prescriptions Pivotal data: 42% reduction in all-cause mortality 50% fewer cardiovascular hospitalizations over 30 months Positions Attruby as a potential first-line standard of care in ATTR-CM. Global Expansion in Motion 🌐 Regulatory approvals secured in Europe, Japan, and the UK. Strategic launch partnership with Bayer to accelerate physician adoption and market penetration. Smart Capital Strategy 💰 Secured $300M in non-recourse funding via partial monetization of European royalties. Funds a strong commercial push while retaining long-term upside from BEYONTTRA™ sales. Robust Pipeline Depth 🧬 Over 30 clinical and pre-clinical programs, offering multiple shots on goal beyond Attruby. Investment Outlook: Bullish Entry Zone: Above $38.00–$39.00 Upside Target: $60.00–$62.00, driven by blockbuster drug momentum, global rollout, and pipeline expansion. 📈 BBIO has the dual advantage of a de-risked lead asset and a rich R&D pipeline—positioning it for sustained multi-year growth. #BBIO #Biotech #Pharma #ATTRCM #Cardiology #DrugLaunch #PipelineGrowth #BayerPartnership #GlobalExpansion #ClinicalTrials #GeneticDiseases #Pharmaceuticals
NASDAQ:BBIOLong
by Richtv_official
Novo Nordisk (Revised) | NVO | Long at $47.78**This is a revised analysis from February 5, 2025: I am still in that position, but added significantly more below $50** Novo Nordisk NYSE:NVO is now trading at valuations before its release of Wegovy and Ozempic... From a technical analysis perspective, it's within my "major crash" simple moving average zone (gray lines). When a company's stock price enters this region (especially large and healthy companies) I always grab shares - either for a temporary future bounce or a long-term hold. While currently trading near $47 a share, I think worst case scenario here in 2025 is near $38-$39. Tariffs may cause a recession in the second half of 2025, so no company would be immune. As mentioned above, I am still a holder at $86.74. However, I went in much heavier within my "major crash" simple moving average band and have a final entry planned near $38-$38 (if it drops there). My current cost average is near $55.00. Why do I still have faith in NYSE:NVO ? Because no one else does right now, yet it generated $42 billion in revenue, $14 billion in profits, and has significant cash flow YoY. The company has a massive pipeline, despite Wegovy and Ozempic competition, and I think the market is undervaluing its position in the pharmaceutical industry. Revised Targets in 2028: $60.00 (+25.6%) $70.00 (+46.5%) $80.00 (+67.4%)
NYSE:NVOLong
by WorthlessViews
Is Novo Nordisk a buy? Novo Nordisk $NYSE: NVO plummets 22% on July 29, wiping out $57.5B in market value! Here's what's happening and how I see it. Here’s the breakdown on why the stock hit its lowest since Nov 2022: Slashed 2025 Guidance: Sales growth cut to 8–14% from 13–21%, operating profit to 10–16% from 16–24%. Weak U.S. demand for Wegovy & Ozempic, plus competition from cheaper compounded GLP-1 drugs (i.e. grey market), cited as key issues. CEO Shake-Up: Lars Fruergaard Jørgensen out, Maziar Doustdar in as CEO effective Aug 7. Investors worry Doustdar’s limited U.S. experience could hurt Novo’s edge in its biggest market (57% of sales). Competition: Eli Lilly’s Zepbound (20.2% weight loss vs. Wegovy’s 13.7%) & Mounjaro are stealing market share. Compounded GLP-1s from Hims & Hers add pricing pressure. Here's what I see: There's a strong bearish sentiment, but the stock is very underpriced. Considering the current stock price, EPS is at an all-time high. This means investors get more earnings for their stock. P/B, P/E, and P/S ratios are at the lowest level since 2017! This is despite revenue growth of 25%+ for 3 consecutive years. Operating margins are still quite healthy. The company still has a very significant share (over 50%) of the GLP1 drugs worldwide. The valuation of this company is now at the best level of the last 7-8 years. There might be more volatility ahead, but I see the recent price drop as an opportunity to buy a pharma giant at a big discount, giving investors a margin of safety. Quick note: I'm just sharing my journey - not financial advice! 😊
NYSE:NVOLong
by HenriqueCentieiro
2
Sarepta's Plunge: A Confluence of Challenges?Sarepta Therapeutics (SRPT) faces significant market headwinds. The company's stock has seen a notable decline. This stems from multiple, interconnected factors. Its flagship gene therapy, ELEVIDYS, is central to these challenges. Recent patient deaths linked to similar gene technology raised safety concerns. The FDA requested a voluntary pause in Elevidys shipments. This followed a "black box warning" for liver injury. The confirmatory EMBARK trial for Elevidys also missed its primary endpoint. These clinical and regulatory setbacks significantly impacted investor confidence. Beyond specific drug issues, broader industry dynamics affect Sarepta. Macroeconomic pressures, like rising interest rates, reduce biotech valuations. Geopolitical tensions disrupt global supply chains. They also hinder international scientific collaboration. The intellectual property landscape is increasingly complex. Patent challenges and expirations threaten revenue streams. Cybersecurity risks also loom large for pharmaceutical companies. Data breaches could compromise sensitive R&D and patient information. The regulatory environment is evolving. The FDA demands more robust confirmatory data for gene therapies. This creates prolonged uncertainty for accelerated approvals. Government initiatives, like the Inflation Reduction Act, aim to control drug costs. These policies could reduce future revenue projections. Sarepta's reliance on AAV technology also presents inherent risks. Next-generation gene editing technologies could disrupt its current pipeline. All these factors combine to amplify each negative impact. Sarepta's recovery depends on strategic navigation. Securing full FDA approval for Elevidys is crucial. Expanding its label and maximizing commercial potential are key. Diversifying its pipeline beyond a single asset could de-risk the company. Disciplined cost management is essential in this challenging economic climate. Collaborations could provide financial support and expertise. Sarepta's journey offers insights into the broader gene therapy sector's maturity.
NASDAQ:SRPTShort
by UDIS_View